Group items tagged

England's chief pharmaceutical officer (CPhO) David Webb has promised his "wholehearted support" for the community pharmacy sector at the board meeting of the National Pharmacy Association (NPA) on 28 June in St Albans. After hearing the CPhO at the meeting, NPA chair, Andrew Lane, later declared: "David is someone we can do business with." Webb thus listed his priorities as head of profession: integration of independent prescribing as part of pharmacy practice by 2026; promotion of inclusive pharmacy practice for all pharmacy professionals; assurance of post-registration practice; developing the role of pharmacy technicians; support for Integrated Care Systems and Primary Care Network pharmacy teams (including community pharmacy); medicines optimisation; and strengthening of professional leadership for community pharmacy. He also reported that NHS England had recently increased its team of regional pharmacy integration leads from seven to 14, creating seven new senior posts. Webb told NPA board members: "I want sincerely to thank community pharmacy teams for everything they are doing and to say that you have my wholehearted support. I believe in the importance of community pharmacy and will listen and engage as I've already demonstrated.

Balmedie Pharmacy based in Aberdeenshire, Scotland has been purchased by local expanding multiple operator JMF Healthcare. Balmedie Pharmacy is a well-performing community pharmacy that dispenses an average of 5,255 items per month. It lies completely unopposed in the large Aberdeenshire village of Balmedie, which is circa eight miles north of Aberdeen City Centre. The pharmacy has been owned by Brian Arris since 2004 and was recently brought to market to allow him to pursue other pharmacy business opportunities. Following a confidential sales process with Christie & Co, JMF Healthcare to benefit from new housing developments in this area of Aberdeenshire such as 300 new homes planned in Balmedie, approved plans for up to 500 new homes in Trump Menie Estate, and 284 new homes planned in Blackdog Village. Brian Arris, previous owner of Balmedie Pharmacy, comments, "I'm sad to see the business go as the excellent staff have helped grow the pharmacy from scratch since 2004 and we've all put our hearts and souls into providing good pharmaceutical care for the village and surrounding area. I'm confident everyone is left in safe hands with John at the helm now."

Recently, the English Health Secretary has talked about introducing a 'Pharmacy First' model similar to that which exists in Scotland. This would be a win-win outcome providing people with better access to essential healthcare support, advice and treatment whilst relieving strain on other parts of the NHS, not least GPs and A&E. It is a no-brainer and yet despite a few media headlines there are still no firm proposals on the table to make this a reality. It surely cannot be right that you can receive a broad range of patient care services in Scotland which are not available in England. It works well in Scotland, Wales is keen to develop more pharmacy-based services and Northern Ireland, leaving aside the current funding dispute, has had a minor ailments service for many years. If the English Health Secretary is sincere in his interest in adopting an English version of the Scottish model, then there are critical aspects he needs to consider. Firstly, start with the patient journey through the healthcare ecosystem from illness prevention through to long-term condition management. What is the role of community pharmacy and how do we guide people to seek support from the most appropriate healthcare professional? What is the vision for community pharmacy delivering patient care in the next decade? The lesson from Scotland is that the government needs to sit down with the sector and map that out together. There are no quick fix overnight solutions. This needs to be a long-term commitment backed by adequate funding. Supervision regulations need to change and there needs to be a thought through workforce strategy which avoids community pharmacy shortages as that does nothing to deliver improved patient outcomes.

The nationwide implementation of the Pharmacy First service is viewed as a significant development that benefits pharmacies, primary care, and the broader National Health Service (NHS). Pharmacy teams are striving to ensure its success despite challenges within the industry landscape. However, not all pharmacists are able to reap the benefits from it. Recently, two members of Numark shared their experiences of how the scheme is impacting their pharmacies. Graham Phillips, who owns Letchworth Pharmacy in Hertfordshire, revealed that patients are responding favourably to the service. "It's all good, people are just delighted to have easier access to care," he said. In its first month, Letchworth Pharmacy provided around 100 consultations, and Phillips envisions that as the service matures, they will be able to conduct an average of 200 interventions per week. "That will make it financially viable for us and mean that we're acting at scale from an NHS perspective. That's 200 GP appointments we've freed up in a week - that's a huge capability and capacity bump for the NHS," he added. Graham credits part of his success with Pharmacy First to the strong relationship he has established with local GPs in his area.

Preet Kaur Gill, Shadow Minister for Primary Care and Public Health, has paid a recent visit to a community pharmacy in Staffordshire to personally experience the services it provides to patients, while staying updated on the latest sector developments. Her visit to Eason's Pharmacy in Tamworth on September 22nd marked her first since assuming new responsibilities for pharmacy policy matters within Labour's health team. Gill was also joined by a member of the National Pharmacy Association staff. The Minister received a comprehensive briefing on Eason's Pharmacy from its third-generation owner, Kieran Eason (R). He outlined the NHS services, which include the New Medicines Service and blood pressure monitoring, and showcased two consultation rooms and an operational dispensary. "It's great that Preet came to learn firsthand about the challenges we face and the substantial potential of community pharmacies nationwide," Eason said. "As an independent prescriber, I have the expertise to provide even more convenient care, but the current funding levels severely limit our contribution."

"Only around half of ICSs have a Chief Pharmacist," indicating a significant gap in leadership that hampers the pharmacy sector's ability to influence critical healthcare decision, a report on medicine optimisation by the Public Policy Projects (PPP) highlights. In PPP's latest report, a notable concern highlighted is the inadequate representation of pharmacy leadership within Integrated Care Systems (ICSs) despite the role of pharmacy being "central in the delivery of system priorities, with pivotal roles in improving population health and tackling inequalities". In recent years, the role of pharmacy within the NHS has evolved significantly with recent developments including Pharmacy First Services and legislative amendments that allows pharmacy technicians under PGDs to administer and supply medicines.

Community pharmacies are located within the very hotspots of peoples' communities, yet a staggering 720 individual businesses have stopped trading since 2015. It has been called a "national disgrace and a betrayal to the elderly and the vulnerable" by sector leaders. The funding crisis has been compounded by a gruelling 18-24 months post-Covid, both have which have placed immense pressure on the retail pharmacy sector. The population is aging and with this comes patients living with a range of long-term health conditions. Medication regimes are becoming ever more complex and as a result, maintaining prescription and medication adherence services is challenging to say the least. Yet the public feel great warmth towards their local pharmacy businesses, and this positive attitude only increased during the pandemic. In fact, in a recent report launched by Omnicell on the Changing Role of the Pharmacist, a survey of public opinion found that a third (32 per cent) said they perception of their local pharmacy had changed for the better since the start of the pandemic and nearly half (44 per cent) said they are more familiar with their local pharmacy services since the start of COVID. This has meant that the role of the pharmacist has also changed and evolved; in part due to a national need and drive for more patients to be seen and supported clinically by pharmacists. This change of service provider role has slowly been developing over the last couple of years. Pharmacists are currently carrying out 65 million consultations a year - a staggering rise of 44 per cent in the last 24 months alone.

Victoria Atkins MP, the new Secretary of State for Health and Social Care, visited NPA board member Sukhi Basra (L) at CliniChem pharmacy in Central London on Thursday (16 November). Basra was accompanied by NPA Chief Executive Mark Lyonette. This was among Atkins' first appointments following her recent promotion in the recent Cabinet reshuffle. Atkins met with staff and patients to explore clinical services and discuss the evolving role of the community pharmacy sector. "Welcoming politicians and officials to my pharmacy is always a pleasure," Basra said. Basra highlighted the opportunity to brief the Health Secretary on the latest developments, including Pharmacy First.

As the general election campaign heats up, major political parties - including Labour, the Conservatives, the Liberal Democrats - have released their manifestos, detailing their plans and visions for the future of community pharmacy. While the Conservative Party promises to expand Pharmacy First initiative, Labour pledges support for small businesses, with plans to overhaul the business rates system. The Liberal Democrats' election manifesto commits to developing a fairer and more sustainable long-term funding model for pharmacies. Announcing their plans recently, Prime Minister Rishi Sunak stated that they are investing in community care services to secure the future of the NHS and make healthcare more accessible. The Conservatives plan to fund these initiatives by cutting NHS managerial positions back to pre-pandemic levels and halving the government's management consultancy expenditure.

In an open letter to pharmacy colleagues, the Royal Pharmaceutical Society (RPS) praised the work being done by them over this "extremely busy period." Expressing gratitude towards pharmacists RPS said "Patients rely on you and we are so proud of the work you are doing." It said the incredible work of pharmacists, in all settings, have ensured that patients have access to medicines and advice during the pandemic. Calling pharmacists an integral part of the profession, RPS said they not only prescribe and advise the public, but also play a key role in teaching future pharmacists, developing new medicines, running and supporting clinical trials.

Workforce issues, staff retention and capacity continues to be a big concern for the Local Pharmaceutical Committee as it discussed the topics at a recent meeting with the Pharmaceutical Services Negotiating Committee (PSNC). The meeting, attended by delegates from 66 LPCs, focused on the current challenges faced by community pharmacies as well as the planning for the next year. Around 64 per cent of delegates said workforce was the top challenge faced by pharmacy contractors, and suggested reducing the migration of pharmacists to Primary Care Networks (PCNs). Other suggestions included - "improving the development opportunities available for pharmacists and their teams, and rebranding the profession to make community pharmacy a more attractive route for young graduates." On the development of Integrated Care Systems (ICS), the majority of respondents were positive about their LPC's engagement in the new setting.

To support NHS, clear the backlog created by the Covid-19 pandemic and help community pharmacies support more people, the Welsh government has announced an allocation of further £12.5 million funding. Of the total amount, £10mn will be distributed across the 22 local authorities to buy equipment to help people to live independently in their own homes post hospital stay. The remainder, £2.5mn, will be used to support community pharmacists and patients to improve access to treatment and advice for a range of common ailments. The move is aimed at alleviating waiting times and reducing winter pressures on the NHS. Commenting on the announcement, Elen Jones, Royal Pharmaceutical Society director for Wales said: "We are delighted that the Welsh government continue to recognise the value of pharmacists in patient care and we welcome this additional investment and support for Community Pharmacy teams across Wales.

The Royal Pharmaceutical Society (RPS) England director, Ravi Sharma, has resigned after four years on the job. He will be leaving the RPS in October to join Luton and Dunstable University Hospital, part of the Bedfordshire Hospitals NHS Foundation Trust group, as head of pharmacy. RPS will be commencing the recruitment of a new director for England shortly and in the interim Ravi will be working with Paul Bennett, the RPS CEO, to help in delivery of key objectives and in the appointment of his successor. Paul commented: "Ravi has made a significant contribution to the organisation during his time with us. His drive and enthusiasm for advancing the recognition of the role of the Society itself and of pharmacists and professional practice is probably best reflected by his desire to ensure a real focus on personalised medicines and his work on equality and diversity, workforce wellbeing, and most recently the development of a new vision for pharmacy in England.

The Pharmacists' Defence Association (PDA) has expressed disappointment at the omission, once again, of the promised Employment Rights Bill omitted from the Queen's Speech earlier this week. The Bill is pledged to strengthen day one employment rights and increase the productivity of businesses. It set out plans which would protect and enhance workers' rights and aim to make the UK the best place in the world to work at. This included plans to introduce the right to request flexible working for around 2.2 million people in Great Britain - regardless of time served in a bid to modernise the way employees work. The PDA said: "The Employment Rights Bill would have presented an opportunity to improve the ability for workers to obtain redress in the event of poor treatment or discrimination through the development of a single labour market enforcement body. "Poor employment practices, such as insecure work through long-term zero-hours contracts, unilaterally changing workers' terms and conditions by terminating their contracts and re-hiring them on new terms and conditions (also known as fire and rehire), and the sacking of workers without notice, as recently demonstrated by P & O Ferries, could have been outlawed under new legislation."

The Royal Pharmaceutical Society (RPS) Scotland the BMA's Scottish GP Committee has called for improvements to the pharmacotherapy service. The joint statement released by the organisations on Friday (13 January), has recognised that much progress has been made but states that further improvements are needed to fully maximise the benefits of the service. It highlighted the need for better use of skill mix, including more clearly defining roles and responsibilities; improved IT enablers to reduce administrative burden; and further developing a tandem model of working comprising hubs with in-practice activity The two organisations state that inadequate funding and workforce shortages are a real threat to the pharmacotherapy service. They have urge Scottish Government to reconsider its recent decision to reduce funding for training pharmacy technicians. Clare Morrison, RPS Director for Scotland, said: "In the statement, we stress that the use of pharmacists' clinical skills must be maximised.

Rosemont Pharmaceuticals (Rosemont) has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK. Through this acquisition Rosemont will expand its existing portfolio and have access to a pipeline of innovative products, providing lifesaving pharmaceuticals to the UK and overseas markets. Founded in 2012, Lucis has grown to become a leading provider in the development and licensing of novel and exclusive medicines. With over a dozen SKUs covering a variety of therapeutic areas, Lucis has established a strong portfolio that, in addition to a pipeline of innovative developments, serve the growing patient need for liquid medicines. The acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22. "As well as continuing to broaden our portfolio and add to our strong growth globally, this acquisition also gives access to pipeline products and developer relationships to accelerate our entry into new product areas such as sachets" said Howard Taylor, Chief Executive Officer of Rosemont.

Recently launched generic version of Apixaban by Teva UK is said to bring savings to the NHS drug bill while making sure patients get the medicine they need. The generic apixaban is available for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA) and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Previously there was only a 'branded' product available, but Castleford-based Teva UK succeeded in invalidating the apixaban patent and SPC (supplementary protection certificate) in the UK High Court and so is now able to launch its own 'generic' version - which will bring savings for the NHS while making sure patients get the medicine they need. "We've always said that we stand up for the patient", said Kim Innes, General Manager of Teva UK and Ireland. "The launch of generic apixaban emphasises Teva's commitment to doing the right thing by putting patients at the heart of everything we do by giving them and the NHS access to affordable treatments." Apixaban is an anticoagulant which directly inhibits factor X (factor Xa), inhibiting thrombin formation and the development of thrombi (blood clots). For at-risk patients, such as those with, or at risk for DVT, or NVAF, the risk of stroke related to blood clots forming in the body and traveling to the brain is a serious concern. Each year, DVT affects around 1 person in every 1,000 in the UK and if left untreated, about 1 in 10 people with a DVT will develop a PE.

Boehringer Ingelheim UK & Ireland has appointed Vani Manja as its new Country Managing Director and Head of Human Pharma. Manja has been associated with Boehringer Ingelheim for over 11 years, in successful leadership roles in Germany, the United States and most recently as General Manager, India. Her career started as a commissioned officer in the Indian Army Ordnance Corps which preceded leadership roles at Becton Dickinson and McKinsey. She brings extensive experience of strategy, marketing, sales, business development, people management, and cultural transformation and is passionate about tackling healthcare inequalities and advancing sustainable healthcare. Commenting on her new role, Manja said: "It is with great heart that I bring the spirit of conscious leadership to my new role. I look forward to being fully present and partnering with key stakeholders in the healthcare ecosystem in our collective quest to improve health for humans and animals in the UK and Ireland."

In partnership with the pharmaceutical company Boehringer Ingelheim, Leeds Teaching Hospitals Trust (LTHT) has recently established an innovative cardiometabolic clinic. The clinic focuses on reducing cardiovascular risk in people with diabetes who have recently been discharged from LTHT following a heart attack. It is delivered jointly by the cardiology department at Leeds General Infirmary and the diabetes services at the Trust. This is a patient-centred approach to reducing that risk, with pharmacist-delivered clinics scheduled for six to eight weeks after the heart attack. Stephen Wheatcroft, Professor of Cardiometabolic Medicine and Consultant Cardiologist at LTHT, said: "This is an exciting and innovative development, one of the first in the country. Previously, Type 2 diabetic patients presenting with heart issues would have been treated by two separate specialty teams. This is the first time there has been a specific clinic combining the cardiac and diabetes team working together. "We aim to reduce the risk for patients, with earlier multidisciplinary hospital care, to help discharged patients achieve better diabetes control, through improved medication support and optimisation, reducing the need for further treatment and future hospital stays. Overall, it will mean a better patient experience, with improved monitoring and information about treatment options, along with a reduction in waiting times for review in a specialist clinic."

Japanese drugmaker Eisai said on Tuesday (January 10) it had submitted a marketing application to the European health regulator for review of its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States. The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease. Nearly all previous experimental drugs using the same approach have failed. The company's application to the European Medicines Agency is based on results from a late-stage study in which the drug was shown to slow down the rate of cognitive decline in patients with early Alzheimer's by 27 per cent, compared with a placebo. Eisai also reiterated its plans to apply for marketing authorization of the drug in Japan by the end of its business year on March 31.